NR567 FINAL EXAM NEWEST 2025/2026
ACTUAL EXAM TEST BANK | NR567
ADVANCED PHARMACOLOGY FOR THE
AGACNP FINAL EXAM QUESTIONS AND
CORRECT ANSWERS (VERIFIED
ANSWERS) PLUS RATIONALES 2026 Q&A
| LATEST EXAM UPDATE 2026/2027
Core Domains
• Pharmacokinetics and Pharmacodynamics: ADME, Receptor
Theory, and Drug Interactions
• Cardiovascular Pharmacology: Antihypertensives,
Antidysrhythmics, Heart Failure, Anticoagulants, and Lipid-
Lowering Agents
• Pulmonary and Renal Pharmacology: Bronchodilators,
Corticosteroids, Diuretics, and Electrolyte Management
• Neurological and Psychiatric Pharmacology: Antiepileptics,
Antidepressants, Anxiolytics, and Antipsychotics
• Infectious Disease Pharmacology: Antimicrobials and
Stewardship
• Endocrine Pharmacology: Insulins, Oral Antidiabetics, Thyroid
Agents, and Corticosteroids
, • Pain Management and Anesthesia: Opioids, NSAIDs, and
Neuromuscular Blockers
• Critical Care and Emergency Pharmacology: Vasopressors,
Inotropes, Sedatives, Antidotes, and Reversal Agents
• Pharmacotherapy in Special Populations: Geriatrics, Renal and
Hepatic Impairment, and Obesity
Introduction
This comprehensive examination assesses the adult-gerontology
acute care nurse practitioner's mastery of advanced pharmacology
for safe and effective prescribing in acute and critical care settings. It
evaluates knowledge of pharmacokinetic principles,
pharmacodynamic mechanisms, pharmacogenomic considerations,
and evidence-based pharmacotherapy for cardiovascular, pulmonary,
renal, neurological, infectious, and endocrine conditions. The
multiple-choice and scenario-based format emphasizes real-world
application, critical thinking, and clinical decision-making.
Candidates are tested on their ability to integrate
pharmacotherapeutic knowledge with patient-specific factors,
hemodynamic monitoring, adverse effect surveillance, and regulatory
compliance to optimize therapeutic outcomes for acutely and
critically ill adults and older adults.
SECTION ONE: QUESTIONS 1–100
,Question 1
A 72-year-old female with congestive heart failure and chronic
kidney disease (eGFR 28 mL/min) is admitted and started on an
antibiotic that is primarily renally eliminated. After two doses, she
complains of nausea and dizziness. Vital signs show HR 98, BP
90/58. Labs reveal rising BUN/creatinine. What is the most likely
pharmacokinetic explanation for her adverse effects?
A. Increased volume of distribution due to fluid overload
B. Reduced renal elimination leading to increased plasma drug
concentration
C. Enhanced hepatic metabolism producing toxic metabolites
D. Increased first-pass effect decreasing drug bioavailability
B. Reduced renal elimination leading to increased plasma drug
concentration
RATIONALE: In patients with impaired renal function, drugs
primarily excreted by the kidneys accumulate, leading to increased
plasma concentrations and toxicity risk. Reduced elimination
prolongs half-life, especially for renally cleared medications. Fluid
overload increasing Vd does not explain acute toxicity, and hepatic
metabolism or first-pass effects are unrelated to declining renal
elimination.
Question 2
A 65-year-old male with alcoholic cirrhosis presents with confusion
and tremor after starting a benzodiazepine for anxiety. Labs show
, significant edema and hypoalbuminemia. Which pharmacokinetic
change most accounts for his increased drug effect?
A. Decreased plasma protein binding resulting in increased free
drug
B. Enhanced renal clearance of active metabolites
C. Reduced absorption from gastrointestinal edema
D. Increased first-pass metabolism through hepatic hyperfusion
A. Decreased plasma protein binding resulting in increased free
drug
RATIONALE: In cirrhosis, reduced plasma protein (especially
albumin) increases the free fraction of highly protein-bound drugs,
enhancing drug effect. Additionally, decreased hepatic metabolism
increases drug exposure. Renal clearance increase is unlikely in
cirrhosis, and first-pass effects typically decrease, not increase, in
liver disease.
Question 3
A drug that acts as a competitive antagonist at muscarinic receptors
is administered to a patient. Which effect would most likely be
observed?
A. Bradycardia and increased salivation
B. Mydriasis and decreased gastrointestinal motility
C. Bronchoconstriction and increased sweating
D. Miosis and increased urinary frequency
B. Mydriasis and decreased gastrointestinal motility
ACTUAL EXAM TEST BANK | NR567
ADVANCED PHARMACOLOGY FOR THE
AGACNP FINAL EXAM QUESTIONS AND
CORRECT ANSWERS (VERIFIED
ANSWERS) PLUS RATIONALES 2026 Q&A
| LATEST EXAM UPDATE 2026/2027
Core Domains
• Pharmacokinetics and Pharmacodynamics: ADME, Receptor
Theory, and Drug Interactions
• Cardiovascular Pharmacology: Antihypertensives,
Antidysrhythmics, Heart Failure, Anticoagulants, and Lipid-
Lowering Agents
• Pulmonary and Renal Pharmacology: Bronchodilators,
Corticosteroids, Diuretics, and Electrolyte Management
• Neurological and Psychiatric Pharmacology: Antiepileptics,
Antidepressants, Anxiolytics, and Antipsychotics
• Infectious Disease Pharmacology: Antimicrobials and
Stewardship
• Endocrine Pharmacology: Insulins, Oral Antidiabetics, Thyroid
Agents, and Corticosteroids
, • Pain Management and Anesthesia: Opioids, NSAIDs, and
Neuromuscular Blockers
• Critical Care and Emergency Pharmacology: Vasopressors,
Inotropes, Sedatives, Antidotes, and Reversal Agents
• Pharmacotherapy in Special Populations: Geriatrics, Renal and
Hepatic Impairment, and Obesity
Introduction
This comprehensive examination assesses the adult-gerontology
acute care nurse practitioner's mastery of advanced pharmacology
for safe and effective prescribing in acute and critical care settings. It
evaluates knowledge of pharmacokinetic principles,
pharmacodynamic mechanisms, pharmacogenomic considerations,
and evidence-based pharmacotherapy for cardiovascular, pulmonary,
renal, neurological, infectious, and endocrine conditions. The
multiple-choice and scenario-based format emphasizes real-world
application, critical thinking, and clinical decision-making.
Candidates are tested on their ability to integrate
pharmacotherapeutic knowledge with patient-specific factors,
hemodynamic monitoring, adverse effect surveillance, and regulatory
compliance to optimize therapeutic outcomes for acutely and
critically ill adults and older adults.
SECTION ONE: QUESTIONS 1–100
,Question 1
A 72-year-old female with congestive heart failure and chronic
kidney disease (eGFR 28 mL/min) is admitted and started on an
antibiotic that is primarily renally eliminated. After two doses, she
complains of nausea and dizziness. Vital signs show HR 98, BP
90/58. Labs reveal rising BUN/creatinine. What is the most likely
pharmacokinetic explanation for her adverse effects?
A. Increased volume of distribution due to fluid overload
B. Reduced renal elimination leading to increased plasma drug
concentration
C. Enhanced hepatic metabolism producing toxic metabolites
D. Increased first-pass effect decreasing drug bioavailability
B. Reduced renal elimination leading to increased plasma drug
concentration
RATIONALE: In patients with impaired renal function, drugs
primarily excreted by the kidneys accumulate, leading to increased
plasma concentrations and toxicity risk. Reduced elimination
prolongs half-life, especially for renally cleared medications. Fluid
overload increasing Vd does not explain acute toxicity, and hepatic
metabolism or first-pass effects are unrelated to declining renal
elimination.
Question 2
A 65-year-old male with alcoholic cirrhosis presents with confusion
and tremor after starting a benzodiazepine for anxiety. Labs show
, significant edema and hypoalbuminemia. Which pharmacokinetic
change most accounts for his increased drug effect?
A. Decreased plasma protein binding resulting in increased free
drug
B. Enhanced renal clearance of active metabolites
C. Reduced absorption from gastrointestinal edema
D. Increased first-pass metabolism through hepatic hyperfusion
A. Decreased plasma protein binding resulting in increased free
drug
RATIONALE: In cirrhosis, reduced plasma protein (especially
albumin) increases the free fraction of highly protein-bound drugs,
enhancing drug effect. Additionally, decreased hepatic metabolism
increases drug exposure. Renal clearance increase is unlikely in
cirrhosis, and first-pass effects typically decrease, not increase, in
liver disease.
Question 3
A drug that acts as a competitive antagonist at muscarinic receptors
is administered to a patient. Which effect would most likely be
observed?
A. Bradycardia and increased salivation
B. Mydriasis and decreased gastrointestinal motility
C. Bronchoconstriction and increased sweating
D. Miosis and increased urinary frequency
B. Mydriasis and decreased gastrointestinal motility
